One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Cardiovascular Systems logo
Cardiovascular Systems CSII
report update icon

Quarterly report 2023-Q2
added 05-30-2026

Cardiovascular Systems Financial Statements 2022-2009 | CSII

Annual Financial Statements Cardiovascular Systems

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

602 M 818 M 1.42 B 1.26 B 1.17 B 770 M 924 M 264 M 1.07 B 759 M 285 M 144 M - -

Shares

39.2 M 38.8 M 34.3 M 33.5 M 33.1 M 32.4 M 32.5 M 31.5 M 28.3 M 21.7 M 18 M 15.9 M 14.7 M -

Historical Prices

15.3 21.1 41.3 37.6 35.4 23.8 28.4 8.36 37.7 35 15.8 9.05 - -

Net Income

-36.9 M -13.4 M -27.2 M -255 K 492 K -413 K 1.04 M -15.2 M -5.27 M -8.66 M -5.77 M -11.1 M -23.9 M -

Revenue

236 M 259 M 237 M 248 M 60.2 M 52.6 M 178 M 182 M 137 M 104 M 82.5 M 78.8 M - -

Cost of Revenue

63.4 M 61.1 M 48.8 M 47.7 M 39.5 M 39.4 M - - - - - - - -

Gross Profit

173 M 198 M 188 M 200 M 48.7 M 43.1 M 40.9 M 33.3 M 35.4 M 25 M 19.4 M 62.5 M 49.8 M -

Operating Income

-35.8 M -11.9 M -26.8 M -825 K 2.23 M -1.54 M -56.1 M -32.6 M -33.5 M -22.4 M -14.5 M -8.81 M -22.9 M -

Interest Expense

1.63 M 1.74 M 1.97 M 1.68 M 1.72 M 500 K - 23 K 1.03 M 1.34 M 1.36 M 1.42 M 1.44 M -

EBITDA

-32.1 M -8.84 M -23.8 M 2.32 M 5.96 M 2.38 M -52.4 M -30.5 M -32.2 M -22.3 M -14.4 M -8.76 M -22.8 M -

Operating Expenses

209 M 210 M 215 M 201 M 175 M 167 M 199 M 175 M 139 M 102 M 77.7 M 71.3 M 72.7 M -

General and Administrative Expenses

171 M 167 M 170 M 168 M 149 M 144 M 163 M 144 M 118 M 86.7 M 66.4 M 62.4 M 62.4 M -

All numbers in USD currency

Quarterly Income Statement Cardiovascular Systems

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

39.7 M 39.6 M 39.7 M 39.3 M 39.2 M 39.1 M 39.2 M 39.1 M 38.9 M 38.9 M 38.8 M 38.7 M 34.1 M 33.9 M 34.1 M 33.6 M 33.5 M 33.4 M 33.5 M 33.2 M 33.1 M 33 M 33.1 M 32.7 M 32.2 M 33 M 32.2 M 32.7 M 32.6 M 32.2 M 32.6 M 31.6 M 31.5 M 31.3 M 31.5 M 30.4 M 27.2 M 24.8 M 27.2 M 21.5 M 20.7 M 20.4 M 20.7 M 18 M 17.9 M 17.7 M 17.8 M 17.5 M 17 M 17 M

Net Income

-7.89 M -10.6 M -7.89 M -9.66 M -8.97 M -8.62 M -8.97 M -8.62 M -6 M -8.62 M -56 K -2.08 M -3.4 M -5.78 M -3.4 M 672 K 492 K -2.89 M 492 K 365 K -413 K -1.98 M -413 K -1.75 M 1.04 M -1.86 M 1.04 M -22.7 M -15.2 M -13.3 M -15.2 M -10.7 M -5.27 M -8.22 M -5.27 M -9.71 M -8.66 M -7.29 M -8.66 M -6.22 M -5.77 M -5.21 M -5.77 M -4.19 M -4.14 M -3.86 M -4.14 M -3.86 M -4.14 M -3.86 M

Revenue

61.5 M 59.7 M 61.5 M 56.2 M 59.1 M 58.4 M 59.1 M 58.4 M 63.3 M 63.3 M 64.2 M 60.5 M 68.3 M 64.5 M 68.3 M 63.3 M 60.2 M 56.3 M 60.2 M 56.3 M 60.2 M 56.3 M 52.6 M 49.7 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

18.5 M 16.7 M 18.5 M 14.8 M 18.1 M 14.3 M 18.1 M 14.3 M 14 M 14 M 13.9 M 12.6 M 13.7 M 12.7 M 13.7 M 12.2 M 11.5 M 10.6 M 11.5 M 10.6 M 11.5 M 10.6 M 9.5 M 9.2 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

43 M 43 M 43 M 41.4 M 41.1 M 44.1 M 41.1 M 44.1 M 49.3 M 49.3 M 50.2 M 48 M 54.6 M 51.8 M 54.6 M 51.1 M 48.7 M 45.7 M 48.7 M 45.6 M 43.1 M 40.5 M 43.1 M 41 M 40.9 M 40.3 M 40.9 M 35.7 M 33.3 M 35.1 M 33.3 M 36.6 M 35.4 M 32.5 M 35.4 M 27.2 M 25 M 22.9 M 25 M 20.2 M 19.4 M 18 M 19.4 M 16.1 M 15.2 M 14.3 M 15.2 M 14.3 M 15.2 M 14.3 M

Operating Income

-8.53 M -10.9 M -8.53 M -9.65 M -8.56 M -8.12 M -8.56 M -8.12 M -5.65 M -5.65 M 283 K -1.66 M -3.37 M -5.93 M -3.37 M 507 K 384 K -2.97 M 384 K 489 K -275 K -1.75 M -275 K -1.76 M 1.08 M -1.87 M 1.08 M -22.7 M -15.1 M -13.2 M -15.1 M -10.5 M -5.25 M -8.19 M -5.25 M -9.59 M -7.5 M -6.85 M -7.5 M -5.41 M -5.12 M -5.21 M -5.12 M -3.72 M -3.66 M -3.1 M -3.66 M -3.1 M -3.66 M -3.1 M

Interest Expense

404 K 406 K 404 K 408 K 409 K 410 K 409 K 410 K 412 K 412 K 412 K 499 K 500 K 472 K 500 K 420 K 422 K 424 K 422 K 429 K 430 K 432 K 430 K 432 K 430 K 432 K 46 K - - - - 1 K 6 K 16 K 6 K 103 K 564 K 281 K 564 K 327 K 345 K 370 K 345 K 370 K 345 K 370 K 279 K 344 K - -

EBITDA

-6.73 M -10 M -8.18 M -6.81 M -6.66 M -7.16 M -8.21 M -7.16 M -3.42 M -5.34 M 587 K -933 K -1.88 M -5.19 M -3.04 M 2.89 M 1.96 M -2.17 M 439 K 3.42 M 1.71 M -758 K -275 K 1.17 M 3.02 M -910 K 1.08 M -20 M -13.3 M -12.3 M -15.1 M -9.25 M -4.5 M -7.82 M -5.25 M -9.46 M -7.39 M -6.82 M -7.5 M -5.27 M -5.02 M -5.18 M -5.12 M -3.68 M -3.66 M -3.1 M -3.66 M -3.06 M -3.66 M -3.1 M

Operating Expenses

51.5 M 53.9 M 51.5 M 51.1 M 49.6 M 52.2 M 49.6 M 52.2 M 54.9 M 54.9 M 50 M 49.6 M 58 M 57.8 M 58 M 50.6 M 48.3 M 48.7 M 48.3 M 45.1 M 43.4 M 42.2 M 43.4 M 42.8 M 39.8 M 42.2 M 39.8 M 58.5 M 48.5 M 48.3 M 48.5 M 47.1 M 40.6 M 40.7 M 40.6 M 36.8 M 32.5 M 29.7 M 32.5 M 25.6 M 24.5 M 23.2 M 24.5 M 19.8 M 18.8 M 17.4 M 18.8 M 17.4 M 18.8 M 17.4 M

General and Administrative Expenses

41.6 M 44.5 M 41.6 M 41.7 M 40.4 M 41.9 M 40.4 M 41.9 M 41.4 M 41.4 M 40.1 M 40.3 M 46.9 M 46.8 M 46.9 M 41.4 M 41.1 M 41.2 M 41.1 M 37.8 M 37 M 35.9 M 37 M 37.3 M 34 M 36.9 M 34 M 42.3 M 41.3 M 41.4 M 41.3 M 39.4 M 32.6 M 33.5 M 32.6 M 31.4 M 27.5 M 25.4 M 27.5 M 21.6 M 20.4 M 20 M 20.4 M 16.8 M 15.7 M 15.4 M 15.7 M 15.4 M 15.7 M 15.4 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Cardiovascular Systems CSII
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Cardiovascular Systems plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 50.65 -1.08 % $ 1.57 B usaUSA
Align Technology Align Technology
ALGN
$ 171.95 -1.33 % $ 12.5 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 45.19 1.11 % $ 66.9 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.48 0.24 % $ 618 M israelIsrael
Medtronic PLC Medtronic PLC
MDT
$ 101.61 -0.08 % $ 130 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 3.32 -1.63 % $ 491 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 0.38 2.01 % $ 24.6 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Insulet Corporation Insulet Corporation
PODD
$ 149.8 1.18 % $ 10.5 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.87 2.47 % $ 238 M canadaCanada
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 31.04 0.4 % $ 26.9 B britainBritain
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.42 3.48 % $ 55.8 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 318.3 -1.85 % $ 122 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
TransMedics Group TransMedics Group
TMDX
$ 92.08 1.25 % $ 3.13 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.43 -0.14 % $ 763 M usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 0.09 4.29 % $ 925 K usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Beyond Air Beyond Air
XAIR
$ 2.55 1.19 % $ 21.2 B usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.28 0.58 % $ 39.1 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 105.96 1.89 % $ 62 B usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 107.01 -0.3 % $ 21.2 B usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Penumbra Penumbra
PEN
$ 321.81 0.12 % $ 12.5 B usaUSA
Myomo Myomo
MYO
$ 1.27 -3.05 % $ 53.2 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.01 -8.38 % $ 128 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA